Treatment of Hypertrophic Cardiomyopathy with Left Ventricular Mid-Cavity Obstruction

Clinical Scenario

This protocol addresses hypertrophic cardiomyopathy in patients with left ventricular mid-cavity obstruction — a specific haemodynamic subtype in which the obstruction occurs within the mid-portion of the left ventricular cavity rather than at the outflow tract.

Treatment Approach

Management in this setting involves high-dose negative chronotropic and negative inotropic pharmacotherapy. Beta-blockers represent a primary consideration, though clinical response in this subtype can be suboptimal.

Full agent selection, dosing strategy, and escalation algorithm available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehad194

Patients with LV mid-cavity obstruction should be treated with high-dose beta-blockers, verapamil, or diltiazem, but the response is often suboptimal.

View source ↗